Schizophrenia News and Research

Latest Schizophrenia News and Research

Researchers use brain imaging to uncover susceptibility to psychological stress and trauma

Most people have intense emotional reactions to traumatizing events like road accidents or combat. But some suffer far longer, caught in the grip of long-term debilitating disorders such as Post-Traumatic Stress Disorder (PTSD). Because doctors cannot predict who will develop these disorders, however, early or preventive intervention is not available. Now, a new project led by researchers at Tel Aviv University seeks to identify pre-traumatic subjects - those who are more susceptible to long-standing disorders if exposed to a traumatic incident.

14 Jun 2012

EnVivo to present results from EVP-6124 Phase 2b trial on AD at AAIC 2012

EnVivo Pharmaceuticals, a company dedicated to developing a broad range of novel central nervous system (CNS) therapies, today announced that the company will present a comprehensive analysis of its recently completed Phase 2b clinical trial of EVP-6124 in Alzheimer's disease at the Alzheimer's Association International Conference 2012 (AAIC), being held July 14-19, 2012 in Vancouver, British Columbia.

14 Jun 2012

Hot weather increases death risk in psychosis patients

Hot weather is associated with increased mortality rates among patients with psychosis, dementia, or substance use disorder, UK research shows.

13 Jun 2012

Specific personality traits linked to suicide risk in schizophrenia

Patients with schizophrenia who have a history of suicide attempts show a different pattern of temperament and character traits compared with their nonsuicidal counterparts, say Turkish researchers.

12 Jun 2012

Epo has performance-enhancing effect on brain, may help treat depression, schizophrenia

Sportsmen and women dope with the blood hormone Epo to enhance their performance. Researchers from the University of Zurich now discovered by animal testing that Epo has a performance-enhancing effect in the brain shortly after injection and not only after days by improving oxygen transport in blood. As Epo also increases motivation, it could be useful in treating depression.

11 Jun 2012

Amylin, Alkermes announce results from BYDUREON clinical study on type 2 diabetes

Amylin Pharmaceuticals, Inc. and Alkermes plc today announced results from the long-term extension of the DURATION-1 study, which showed that BYDUREON (exenatide extended-release for injectable suspension), the first and only once-weekly treatment for type 2 diabetes, was associated with clinically significant and sustained improvements in glycemic control during four years of treatment in adults with type 2 diabetes.

11 Jun 2012

Eye-viewing tests identify schizophrenic patients

Viewing tests that detect eye movement can accurately identify patients with schizophrenia, research shows.

8 Jun 2012

'Coolness' loses much of its historical origins

Research led by a University of Rochester Medical Center psychologist and published by the Journal of Individual Differences has found the characteristics associated with coolness today are markedly different than those that generated the concept of cool.

8 Jun 2012

Low pre-morbid IQ not associated with psychosis risk

The strong correlations currently observed between low IQ and risk for psychosis are most likely linked to the influence that psychosis onset has on cognitive functioning rather than a shared genetic background, suggest study findings.

7 Jun 2012

Pathophysiologic differences evident between schizophrenia, bipolar

Review findings reveal differences in the pathophysiology of bipolar disorder and schizophrenia, relating specifically to the medial temporal lobe and associated limbic regions.

7 Jun 2012

BioLineRx receives two U.S. patent allowances for BL-1021 to treat neuropathic pain

BioLineRx, a biopharmaceutical development company, announced today that two Notices of Allowance have been issued by the United States Patent and Trademark Office (USPTO) for BL-1021, an orally available small molecule for treating neuropathic pain.

6 Jun 2012

UCSD researchers receive $4M NIMH grant to study accelerated biological aging in schizophrenia

Researchers at the Stein Institute for Research on Aging at the University of California, San Diego have received a $4 million grant from the National Institute of Mental Health (NIMH), part of the National Institutes of Health, to study accelerated biological aging in schizophrenia.

6 Jun 2012

Scientists discover previously unrecognized signaling network disrupted in lung cancer

A team of researchers led by Dr. Goutham Narla at Case Western Reserve University School of Medicine in collaboration with scientists at Mount Sinai School of Medicine in New York, have discovered a previously unrecognized signaling network disrupted in lung cancer that can be turned back on by a novel combination of two previously approved FDA drugs.

2 Jun 2012

Subtle executive impairments indicate familial schizophrenia risk

The unaffected first-degree relatives of patients with schizophrenia show subtle executive function impairments, and these deficits are associated with negative symptoms, investigators report.

1 Jun 2012

Feds announce effort to slash inappropriate use of antipsychotic drugs in nursing homes

An estimated 40 percent of nursing home residents with dementia receive the drugs, which are approved to treat schizophrenia and bipolar disorder.

1 Jun 2012

Over half of FEP patients achieve symptomatic remission

More than half of patients with a first episode of psychosis achieve symptomatic remission after 2 years of treatment, but recovery rates are lower, results from a Singaporean study show.

31 May 2012

New method can solve 3-D structures of integral membrane proteins

A new method for rapidly solving the three-dimensional structures of a special group of proteins, known as integral membrane proteins, may speed drug discovery by providing scientists with precise targets for new therapies, according to a paper published May 20 in Nature Methods.

31 May 2012

Topline results from Alkermes’ ALKS 37 phase 2b study on opioid-induced constipation

Alkermes plc today announced topline results from a phase 2b dose-ranging clinical study of ALKS 37 in the treatment of opioid-induced constipation. The multicenter, randomized, double-blind, placebo-controlled, repeat-dose study was designed to assess the safety, tolerability, pharmacokinetic profile and efficacy of ALKS 37 in approximately 150 patients.

31 May 2012

Transcranial stimulation technique reduces hallucinations

Transcranial direct-current stimulation is effective for the treatment of auditory hallucinations in patients with schizophrenia, study results show.

30 May 2012

Patients with mental health issues overwhelm ERs

Patients suffering from schizophrenia, psychotic tendencies and suicidal behaviors are burdening hospital ERs, reports Modern Healthcare.

30 May 2012

Schizophrenia News and Research

Latest Schizophrenia News and Research

Researchers use brain imaging to uncover susceptibility to psychological stress and trauma

EnVivo to present results from EVP-6124 Phase 2b trial on AD at AAIC 2012

Hot weather increases death risk in psychosis patients

Specific personality traits linked to suicide risk in schizophrenia

Epo has performance-enhancing effect on brain, may help treat depression, schizophrenia

Amylin, Alkermes announce results from BYDUREON clinical study on type 2 diabetes

Eye-viewing tests identify schizophrenic patients

'Coolness' loses much of its historical origins

Low pre-morbid IQ not associated with psychosis risk

Pathophysiologic differences evident between schizophrenia, bipolar

BioLineRx receives two U.S. patent allowances for BL-1021 to treat neuropathic pain

UCSD researchers receive $4M NIMH grant to study accelerated biological aging in schizophrenia

Scientists discover previously unrecognized signaling network disrupted in lung cancer

Subtle executive impairments indicate familial schizophrenia risk

Feds announce effort to slash inappropriate use of antipsychotic drugs in nursing homes

Over half of FEP patients achieve symptomatic remission

New method can solve 3-D structures of integral membrane proteins

Topline results from Alkermes’ ALKS 37 phase 2b study on opioid-induced constipation

Transcranial stimulation technique reduces hallucinations

Patients with mental health issues overwhelm ERs

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Schizophrenia News and Research

Latest Schizophrenia News and Research

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Newsletters you may be interested in